How Do Investors React to Investment-Opportunity Shock? Evidence from the COVID-19 Pandemic and Taiwan Bio-Tech Firms

preprint OA: closed
🔓 Open OA copy View at publisher

Abstract

While the stock market crashed in the first quarter after the outbreak of COVID-19, this paper finds that bio-tech firms and their investors could take advantage of the COVID-19 investment opportunity and earn positive abnormal returns. Bio-tech firms earn abnormal returns of 1.63% per day—which can be translated into average capital gains of about 86.7 million NT dollars per day— around the event day on which the WHO declared COVID-19 a global emergency. Positive returns continue after the event day. Moreover, small firms and firms that enjoy greater patent originality and receiving government R&D subsidies earn higher abnormal returns.

My notes (saved in your browser only)

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-05-19T01:45:01.086888+00:00
unpaywall
last seen: 2026-06-13T06:42:57.164913+00:00